#KyowaKirin
LightNews LightNews
oddlytruejp.bsky.social
💊 Japan keeps drug prices low by design. That has now become an American export.

Astellas and Kyowa Kirin signed most-favored-nation deals with Washington — the first Japanese drugmakers to do so. US prices get benchmarked against Japan's.

#DrugPricing #Astellas #KyowaKirin
September 5, 2026 at 10:00 PM
4040rec.bsky.social
#Drugpricing #MFN #MostFavouredNation #Alcon #Astellas #BeOne #BridgeBiotherapeutics #CSL #KyowaKirin #SunPharma #Teva #UCB #MostFavouredNationpricingdeals #MFNpolicy #pharmaindustry #tariffs #GENEROUSprogramme #Medicaid #GLOBE #GUARD #APIs #InflationReductionAct
zurl.co/qxnTx
White House signs pricing deals with nine more pharmas
Nine mid-sized pharmas have signed up for the Trump administration's Most Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.
pharmaphorum.com
September 9, 2026 at 8:21 AM
jlsweekly.bsky.social
JLSW Daily Brief #092 (Sep 9): Kyowa Kirin's anti-VEGF eye drop KHK4951 misses primary endpoint in nAMD Ph2. Medipal names new CEO after 14 yrs. Novo halts 2 more heart trials.

#KyowaKirin #NovoNordisk #LifeSciencesJapan
https://jlsweekly.substack.com/p/vegfkhk4951p2novo-nordisk2
September 8, 2026 at 9:16 PM
4040rec.bsky.social
#Amgen #KyowaKirin #rocatinlimab #atopicdermatitis #phase3study #ASCENDstudy #Tcellrebalancingtherapy #OX40receptor #drugsafety #efficacy #ROCKETtrial #primaryendpoint #secondaryendpoints #HORIZONtrial #IGNITEtrial #rocatinlimabmonotherapy #OX40inhibition
pmlive.com/pharma_news/...
Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis - PMLiVE
The phase 3 study included around 2,600 patients
pmlive.com
September 23, 2025 at 8:23 AM
pharmaphorum.bsky.social
#KyowaKirin has terminated all clinical trials of its anti-OX40L antibody #rocatinlimab, after cases of #cancer were seen in patients taking the drug.

pharmaphorum.com/news/cancer-...
Cancer risk scuppers Kyowa Kirin's autoimmune disease drug
Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.
pharmaphorum.com
March 4, 2026 at 2:28 PM
prismmarketview.bsky.social
BridgeBio ( #$BBIO) plans to present full Phase 3 PROPEL 3 results for its oral achondroplasia drug infigratinib at ICCBH 2026 after reporting strong growth and body proportionality data in children.
#BBIO #KyowaKirin #achondroplasia #raredisease #biotech

prismmarketview.com/bridgebios-o...
BridgeBio’s Oral Infigratinib Shows Strong Phase 3 Growth Data in Children With Achondroplasia
BridgeBio Pharma Inc. (NASDAQ: BBIO) announced Phase 3 data for its oral achondroplasia therapy infigratinib from the PROPEL 3 trial at ICCBH 2026, putting a po
prismmarketview.com
June 22, 2026 at 12:23 PM
ihealthvisiting.bsky.social
If at #iHVEBP2025 in-person be sure to visit our wonderful partner #RocketHealthcare & our exhibitors at their stands to find out more about their fantastic work @UKHSA #BBCtinyhappypeople @ChatHealthNHS @forbabyssake@birth_better @nmcnews#NIHRNursingMidwifery @HarrysHAT5 #KyowaKirin @Booktrust
May 8, 2025 at 10:34 AM